We performed a genome-wide analysis of promoter associated CpG island methylation using methylated CpG island amplification (MCA) coupled to representational differential analysis (RDA) or a DNA promoter microarray in acute lymphoblastic leukemia (ALL). We identified 65 potential targets of methylation with the MCA/RDA approach, and 404 with the MCA/array. Thirty-six (77%) of the genes identified by MCA/RDA were shared by the MCA/array approach. Chromosomal location of these genes was evenly distributed in all autosomes. Functionally, 303 of these genes clustered in 18 molecular pathways. Of the 36 shared genes, 31 were validated and 26 were confirmed as being hypermethylated in leukemia cell lines. Expression analysis of eight of these genes was epigenetically modulated by hypomethylating agents and/or HDAC inhibitors in leukemia cell lines. Subsequently, DNA methylation of 15 of these genes (GIPC2, RSPO1, MAGI1, CAST1, ADCY5, HSPA4L, OCLN, EFNA5, MSX2, GFPT2, GNA14, SALL1, MYO5B, ZNF382 and MN1) was validated in primary ALL samples. Patients with methylation of multiple CpG islands had a worse overall survival. This is the largest published list of potential methylation target genes in human leukemia offering the possibility of performing rational unbiased methylation studies in ALL.
Introduction
Acute lymphoblastic leukemia (ALL) is characterized by a block in differentiation of early lymphoid progenitors, which leads to an accumulation of immature lymphoblasts. 1 Together with genetic changes, epigenetic alterations such as aberrant DNA methylation of promoter associated CpG islands (CGIs) have a role in downregulation of tumor suppressor genes and in the molecular pathogenesis of ALL. 2 Prior data from several laboratories have indicated that aberrant DNA methylation of multiple CGIs is common in ALL 3, 4 and is associated with poor prognosis. [5] [6] [7] Furthermore, we have demonstrated that methylation patterns at relapse are stable in a majority of patients with ALL, 8 and that the identification of residual methylation levels is associated with a higher risk of relapse in patients in morphological remission (H Yang, submitted). We have also demonstrated that the reactivation of an epigenetically silenced gene, such as p57 KIP2 , results in selective induction of apoptosis only in cells in which the gene is methylated. 2 This body of information indicates that epigenetic silencing of tumor suppressor genes is important in ALL.
Until recently, one of the limitations of studying DNA methylation has been the process to select gene(s) to study. It is possible that several hundred genes could be aberrantly methylated and silenced in ALL. 9 Some of these genes may be bona fide tumor suppressor genes, whose silencing could be essential to the pathogenesis of ALL, whereas others may be silenced as a consequence of global methylation dysregulation and not directly involved in oncogenesis. 10 Therefore, an unbiased whole genome approach to identify methylation silenced genes in ALL may reveal novel tumor suppressor genes and enhance our understanding of the role of aberrant gene methylation in this disease. To approach this, we have performed two large-scale genome-wide studies of aberrantly methylated CpG islands in ALL.
Materials and methods

Cell lines and ALL patient samples
The following human leukemia cell lines were studied: of lymphoid origin; MOLT4, Jurkat, Peer, T-ALL1, CEM, J-TAG, B-JAB, RS4, ALL1, Raji, REH and Ramos. Of myeloid origin: K562 and BV173, HL60, NB4, THP1, U937, ML1, OCI, HEL, MOLM13 and KBM5R. All were obtained from the American Type Culture Collection and were cultured in RPMI 1640 (Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal calf serum (Gemini Bio-Products, West Sacramento, CA, USA) and penicillin-streptomycin (Invitrogen). Cell suspensions from bone marrow aspiration specimens from patients with ALL were obtained prior to any therapy and were stored at established tissue banks at MD Anderson Cancer Center (MDACC) following institutional guidelines. All samples were collected using Ficoll-Paque density centrifugation. DNA was extracted from leukemia cell lines and ALL samples using standard phenol-chloroform methods.
Methylated CpG island amplification/representational difference analysis
The principle underlying methylated CpG island amplification (MCA) involves amplification of closely spaced methylated SmaI sites (CCCGGG) to enrich for methylated CGIs.
11 About 70% of CGIs contain two SmaI sites spaced closely enough (200-1000 bases) to be amplified efficiently by PCR. Representational difference analysis (RDA) is a subtraction hybridization step used to identify CGIs methylated specifically in tester DNA. This procedure was performed as described previously.
11 MCA amplicons were generated from a pool of DNA from three patients with ALL (testers). Of importance, the three ALL tester patients were selected because they were refractory to induction therapy with hyperCVAD chemotherapy. 12 These three patients were diploid (Mixed Lineage Leukemia (MLL) and Philadelphia (Ph) chromosome negative). One was a male and two females. Their median age was 33 years (range 27-66). Therefore, this represents a group of patients with very poor prognosis not currently identifiable with current molecular techniques. As control, we used MCA amplicons generated from a pool of DNA from two healthy donors (drivers). These controls were one male and one female, and their ages were 30 and 55 years (median 42.5), respectively (P ¼ 0.48). Briefly, 5 mg of genomic DNA was digested with 100 units of SmaI (New England Biolabs, Ipswich, MA, USA) twice and then further digested with 20 units of XmaI (New England Biolabs). RMCA adaptor was prepared by annealing of oligonucleotides RMCA 24 and RMCA 12, and ligated to the digested DNA fragments using T4 DNA ligase (New England Biolabs). To amplify hypermethylated DNA fragments, PCR was performed using 3 ml of each of the ligation mixture as a template in a 100 ml volume containing 100 pmol RMCA 24 primer, 5 units of Taq DNA polymerase (Life Technologies, Inc., Carlsbad, CA, USA), 4 mM MgCl 2 , 16 mM of NH4 (SO4) 2 , 10 mg/ml of bovive serum albumin, and 5% v/v dimethylsulphoxide. The reaction mixture was incubated at 72 1C for 5 min and at 95 1C for 3 min, and then was subjected to 25 cycles of 1 min at 95 1C and 3 min at 77 1C followed by a final extension of 10 min at 77 1C.
Representational difference analysis was performed on the test and driver MCA amplicons as described previously.
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Primers used for the first and second rounds of RDA were JMCA24/JMCA12, and NMCA24/NMCA12. After the second round of hybridization and selective amplification, the MCA/ RDA products were cloned into a pCR 4.0-TOPO vector (Invitrogen). To screen for inserts, a total of 800 clones were sequenced at a core facility (MDACC). Sequence homologies and chromosomal localization were identified using the Human Blat program (http://www.genome.ucsc.edu). A list of primers used in this study is shown in Supplementary Table 1.
MCA/human proximal promoter DNA microarray
The MCA amplicons generated above were labeled with Cy5-dUTP (tester) or Cy3-dUTP (driver) according to the manufacturer's protocol (Invitrogen). Five micrograms of Cy5-and Cy3-labeled MCA amplicons were mixed and hybridized to the Agilent human proximal promoter microarray slides. These contain approximately 17 000 of the best defined human transcript associated promoters covering À1.0 kb upstream and þ 0.3 kb downstream from the transcription start site (Agilent Technologies, Santa Clara, CA, USA). The hybridization reaction was carried out in rotisserie hybridization oven at 65 1C, 10 r.p.m. for 40 h and subsequently washed following the Agilent aCGH array hybridization protocol. Hybridized slides were scanned using an Agilent G2565AA scanner (Agilent Technologies). The data from scanned microarray images was extracted using Agilent feature extraction software. Image analysis was done using the Agilent G4477AA Chip Analytics 1.2 software package. Genes corresponding to each promoter DNA spotted on the array were identified and then selected by the following criteria: a tester's Cy5 signal intensity of more than 2000 and a Cy5 signal intensity ratio of tester versus driver of more than 2. Promoter specific CGI methylation was further determined using an in silico gene-filtering search method. Genes containing CGI in their promoter regions based on results from USCS Human Blat analysis (http://www.genome.ucsc.edu) and having two putative SmaI cutting sites in their CGIs (putative MCA targets) were selected for further validation.
DNA bisulfite treatment and bisulfite pyrosequencing
Bisulfite treatment of genomic DNA was performed as described. 13 Please refer to Supplementary Information for further details.
Bisulfite sequencing
Bisulfite sequencing was performed to confirm the pyrosequencing results in selected samples. Please refer to Supplementary Information for further details.
RNA preparation and real-time PCR
Methods are described in Supplementary information.
5-aza-2
0 -deoxycytidine and/or trichostatin A treatment
To study the effect of epigenetic modulation, leukemia cell lines were cultured in media supplemented with 5 mmol/l of 5-aza-2 0 -deoxycytidine (Sigma, St Louis, MO, USA) for 4 days, 5 mmol/l of 5-aza-2 0 -deoxycitidine for 4 days and then 500 nmol/l trichostatin A (TSA) (ICN Biomedicals, Costa Mesa, CA, USA) for the last 24 h or 500 nmol/l TSA for 24 h alone. Cells were split 12-24 h before treatment. Mock-treated cells were cultured similarly.
Methylation loci mapping and molecular pathway analysis
The MapChart program (http://www.biometris.wur.nl/UK/Software/MapChart/download) was used to generate a chromosomal map of methylation loci. The ingenuity pathway program (http://analysis.ingenuity.com) was used to cluster gene function and signaling pathway networks.
Statistical analysis
Statistical analyses were performed using Prism 4 (GraphPad Software, Inc.) or Statistica 6 software (Statistica for Windows version 6.0, StatSoft, Tulsa, OK, USA). The Fisher's exact test and t-tests were used to compare gene methylation frequencies or expression levels in leukemia cell lines or ALL patients and normal control groups. The Spearman non-parametric test was used to determine correlations. Effect on survival was analyzed as previously described. 5 All reported P values were two-sided, and Po0.05 was considered statistically significant.
Results
Global identification of hypermethylated genes in Ph negative ALL using MCA/RDA and MCA/microarray techniques First, we used the MCA/RDA approach to identify aberrantly methylated CGIs in ALL. We recovered and sequenced 800 clones. Chromosomal locations, gene homology and CGI information of the sequenced clones were analyzed using the Human Blat program (http://www.genome.ucsc.edu). Of the 800 clones, 217 (27%) contained CGIs, 74 (9.3%) were localized within or close to (o200 bp) the promoter region of identifiable genes and 62 of these 74 clones were matched to known human gene sequences (Supplementary Table 2 ). Of note, five of these clones contained bidirectional promoters.
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These corresponded to either two known genes, or to one known gene, one mRNA/or spliced EST. In total, therefore, 65 genes were identified. Table 1 Methylation profile of leukemia cell lines and normal controls Bisulfite pyrosequencing was carried out to determine the methylation status of selected genes in 23 leukemia cell lines and 10 normal peripheral lymphocytic cells (control). Each column represents a cell line number, and each row indicates a gene identified by both methylated CpG island amplification/representational difference analysis (MCA/RDA) and MCA/DNA promoter microarray. Green box, methylation density o15%; yellow box, methylation density between 15-29.99%; pink grey box, methylation density 30-59.99%; red box, methylation density 460%. Methylation density 415% was used as the cutoff for hypermethylation. Methylation frequency was counted as the percentage of positive methylation numbers versus total numbers studied for each gene. P-values were calculated using a t-test comparing cell line methylatyion versus normal controls.
Due to limited yield of this approach, we performed a second genome-wide DNA methylation search using the MCA/DNA promoter microarray method. This analysis revealed that 923 (5.4%) of the 17000 promoter specific transcripts featured on the Agilent chip were expected to be hypermethylated in Ph negative ALL samples. We further reduced the number of candidate genes by excluding unknown genes (spliced EST, mRNA and hypothetical proteins), sex chromosomal genes and genes whose putative function were not related to oncogenesis, and focused on 404 autosomal genes (Supplementary Table 3 ). We then compared the genes identified by the two techniques: MCA/RDA and MCA/microarray. Of the 65 known genes identified by MCA/RDA, only 47 were represented in the array, 36 of them (77%) were found to be hypermethylated by the MCA/microarray approach. Information on these genes is shown in Supplementary Tables 2 and 3. 19 This data validated the techniques used here. To further demonstrate that other genes identified by these techniques were also aberrantly methylated in leukemia, we selected 31 genes that had been identified both by the MCA/RDA and MCA/array. These included: WNT2B, GIPC2, RSPO1, LHX4, TRIMP58, ECRG4, MAGI1, CAST1, ADCY5, HSPA4L, ZFP42, OCLN, EFNA5, MSX2, GFPT2, PNMA2, GNA14, FOXE1, CRTAC1, DPYSL4, FANK1, DCAMKL1, AGC1, SALL1, SLC13A5, PTPRM, MYO5B, FBX027, ZNF382, MN1, PCDH11. Methylation validation was performed using bisulfite pyrosequencing in 23 leukemia cell lines, 10 normal controls and the 3 Ph negative ALL samples originally used for MCA. Methylation results are shown in Table 1 , Figure 1 and Table 2 . Five genes (TRIMP58, ECRG4, ZFP42, FANK1 and FBXO27) were found methylated in both leukemia cells lines and normal controls samples (Table 1) , and were considered as non-informative. The other 26 genes were methylated in at least 2 of the 23 leukemia cell lines but not or rarely in normal control samples (Table 1) . Spearman coefficient analysis of the 26 genes in leukemia cells revealed that methylation of these genes was generally correlated with each other (Supplementary Table 4 ).
Validation of methylation target genes in leukemia cell lines
Analysis of gene methylation in primary ALL
We subsequently evaluated the methylation status of 15 randomly selected genes of the 31 genes analyzed in cell lines in 61 pretreatment samples from patients with ALL. Patient characteristics are shown in Supplementary Table 4 . Results are shown in Figure 1 and Table 2 . Using a methylation cutoff of Table 2 Methylation profile of primary ALL samples and normal controls
Bisulfite pyrosequencing was carried out to determine the methylation status. Each row indicates a gene identified by both methylated CpG island amplification/representational difference analysis (MCA/RDA) and MCA/DNA promoter microarray. White box, not done; green box, methylation density o15%; yellow box, methylation density between 15-29.99%; pink grey box, methylation density 30-59.99%; red box, methylation density 460%. Methylation density 415% was used as the cutoff for hypermethylation. Methylation frequency was counted as the percentage of positive methylation numbers versus total numbers studied for each gene. MCA tester and drivers are the results on the patient samples used for the MCA experiement. P-values were calculated using a t-test comparing cell line methylatyion versus normal controls. 
DNA Methylation in ALL
S-Q Kuang et al 15% (as described previously), 3 methylation frequencies (percent of patients in which a gene was methylated) ranged from 23 to 100%. Two patients had methylation of 1 gene, 2 of 2 genes, 3 of 3 genes, 14 of 4 genes, 8 of 5 genes, 8 of 6 genes, 11 of 7 genes, 7 of 8 genes, 5 of 9 genes and 3 of 10 genes. No patient had methylation of more than 11 genes.
To further confirm the results of the pyrosequencing assays, DNA methylation of RSPO1, ADCY5, HSPA4L and MYO5B was confirmed in one ALL sample, one normal control and the Raji cell line using bisulfite sequencing. Sequencing results were in concordance with the results obtained by pyrosequencing (Supplementary Figure 1) . Spearman coefficient analysis of all 15 genes revealed that methylation of these genes was significantly correlated with each other (Supplementary Table  4 ). We also observed an excellent correlation between cell line methylation results and patients (data not shown).
Gene expression and effect of epigenetic modulation
To examine the role of the DNA methylation in the control of gene expression, eight genes were studied. [20] [21] [22] [23] [24] [25] [26] [27] Leukemia cell lines were treated with 5-aza-2 0 -deoxycytidine with or without TSA. In general, expression of GIPC2, MAGI1, ADCY5, HSPA4L, OCLN, EFNA5, GNA14 and MYO5B was restored in methylated leukemia cell lines by either 5-aza-2 0 -dexocytidine with or without TSA (Figure 2) , a phenomenon associated with gene demethylation (data not shown). These data indicates that the DNA methylation and histone deacetylation of the genes analyzed here are associated with suppressed gene expression in leukemia cell lines. Furthermore, a relationship was also observed between methylation and gene expression in primary ALL samples (Figure 2 ).
Physical mapping of methylated loci and pathway analysis of microarray data
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Exploratory analysis of effect of DNA methylation in survival
Prior studies have indicated a relationship between hypermethylation of multiple genes and worse survival. 5, 6 To explore this effect, we analyzed the impact of methylation of gene(s) on overall survival. To do this analysis, patients were divided into three groups: those with methylation (X15%) of 0-3 genes, 4-7 genes and 8-10 genes. The median survival of patients in the first group of patients had not been reached, whereas it was 173 weeks for the second group and 68 weeks for the third group (P ¼ 0.012) (Figure 4 ).
Discussion
Using MCA/RDA and an MCA/DNA promoter microarray, we identified a large cohort of genes that are potential targets of aberrant DNA methylation in ALL. Using MCA/RDA we identified 65 targets of aberrant DNA methylation, and with the MCA/array 404. Thirty-one of the genes (77%) were identified by both techniques. Of these 31 genes, 26 genes were found to be informative in cell lines (not methylated in normal controls), and 15 genes were confirmed to be methylated in primary ALL samples. None of the genes that were validated as informative in cell lines was discarded by the analysis of primary ALL samples. Furthermore, a number of these genes had been already shown to be hypermethylated in cancer. This evidence further demonstrates the validity of the assays used here.
In the current study, and as a proof of principle, we validated the methylation of 31 genes not previously reported to be hypermethylated in ALL. Methylation analysis excluded TRIMP58, ECRG4, ZFP42, FANK, DHX32 and FBXO27 as they were found to be methylated in normal controls. The other 26 genes were found to be specifically hypermethylated in leukemia cell lines, and 15 of them were further confirmed to be hypermethylated in a panel of 61 ALL patients. Methylation of these genes was highly correlated both in cell lines and primary samples. Thus, confirming the presence of a hypermethylator phenotype in ALL, as described previously. 3 To demonstrate that the level of methylation identified here was associated with gene expression inactivation, we studied the effect of treating cell lines with a hypomethylating agent with or without a histone deacetylase inhibitor. As expected, treatment of cell lines with these epigenetic modulators resulted, in general, in gene reactivation, an effect that was mediated by induction of DNA hypomethylation. An inverse relationship between methylation and gene expression was also observed in primary ALL samples.
Targets of aberrant DNA methylation were evenly distributed in all autosomes with no evidence of particular chromosomal hot spots for methylation. The function of these genes clustered in 29 different networks involved in multiple cellular functions.
Finally, and as described in other previous studies, 5, 6 methylation of multiple genes was associated with a worse outcome. Those patients with methylation of more than four genes appeared to have a significant worse outcome when treated with hyperCVAD based chemotherapy. The implications of this work are very significant. First, we have made public the largest list of potential targets of aberrant DNA methylation in ALL. This provides a significant source to perform further studies of DNA methylation in ALL, and potentially other leukemias. We provide information that these genes cluster together in specific functional networks and chromosomal locations. This provides the opportunity to investigate specific functions of genes located in specific chromosomal locations. It should be noted that this is not the first large-scale analysis of methylation in ALL. Recently, Taylor et al. 28 reported on 262 methylated genes using a different CGI microarray method. We compared the gene lists identified by our method and their CGI array and found that only nine genes (NASP, FEV, HRB, EFNA5, GTPBP2, RPIB9, CAV1, NOV and SMC2L1) were concordant. This probably relates to the different methods used, in particular the regions analyzed, and the data is probably complementary and it argues that potentially other targets of methylation exist that have not been identified by these two studies combined. It also should be noted that we have identified a number of genes methylated in normal samples. The significance of this observation is not known at the present time.
In summary, we have identified a group of aberrantly methylated genes that can be used as potential epigenetic biomarkers of ALL. We have demonstrated that ALL exhibits widespread epigenetic alterations. Although probably not all methylation events identified here are relevant, clinically or functionally, in ALL directly, the study of this group of genes may provide further insights into the pathogenesis of ALL.
